Novartis reported 202M in Interest Expense on Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alcon AG ALC:SW 31M 1000K
Amgen AMGN:US $ 296M 15M
Biogen BIIB:US $ 66.3M 9.9M
Bristol Myers Squibb BMY:US $ 328M 2M
Eli Lilly And LLY:US $ 83.6M 3.3M
Fresenius Medical Care FME:GR € 84M 0.83M
Genmab GEN:DC 4M 1000K
Gilead Sciences GILD:US $ 250M 6M
Lonza Group LONN:SW 29M 7M
Novartis NOVN:VX 202M 1000K
Novartis NVS:US $ 202M 1M
Pfizer PFE:US $ 325M 9M
Recordati REC:IM 4.42M 158K
Regeneron Pharmaceuticals REGN:US $ 14.2M 0.2M